RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events

Transplantation

Volumn 61, Issue 11, 1996, Pages 1637-1642

  Geiselhart, Lisa ^a   Conti, David J ^a   Freed, Brian M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; CYCLOSPORIN; DNA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MITOGENIC AGENT; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RNA; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FLUORESCENCE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CYCLOSPORINE; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; INDOLES; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; PROTEIN KINASE C; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0029894304     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199606150-00015     Document Type: Article

References (32)

1. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136.
2. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacological probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519.
3. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993; 14: 290.
4. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385.
5. Isakov N, Altman A. Human T lymphocyte activation by tumor promoters: role of protein kinase C. J Immunol 1987; 138: 3100.
6. Weiss A, Wiskocil R, Stobo J. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pre-translational level. J Immunol 1984; 133: 123.
7. Weiss A, Shields R, Newton M, Manger B, Imboden J. Ligand-receptor interactions required for commitment to the IL-2 gene. J Immunol 1987; 138: 2169.
8. Farrar WL, Ruscetti FL. Association of protein kinase C activation with IL-2 receptor expression. J Immunol 1986; 136: 1266.
9. Larsen CS, Christiansen NO. Induction of high-affinity IL-2 receptors on human T lymphocyte: the role of calcium and protein kinase C. Scand J Immunol 1989; 30: 285.
10. Depper JM, Leonard WJ, Krönke M, et al. Regulation of interleukin-2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 1984; 133: 3054.
11. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Increase in cytosolic free calcium is an intracellular messenger for the production of interleukin-2 but not for expression of the interleukin-2 receptor. J Immunol 1985; 134: 1640.
12. Truneh AF, Albert F, Golstein P, Schmitt-Verhulst AM. Early steps of lymphocyte activation bypassed by synergy between calcium ionophore and phorbol ester. Nature 1985; 313: 318.
13. Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J. The role of the T3/antigen receptor in T cell activation. Annu Rev Immunol 1986; 4: 593.
14. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Interleukin-2 induced lymphocyte proliferation is independent of increase in cytosolic-free calcium concentrations. J Immunol 1985; 134: 2431.
15. Kim DK, Otten G, Moldwin RL, Dunn DE, Nau GF, Fitch FW. PMA alone induces proliferation of some murine T cell clones but not others. J Immunol 1986; 137: 2755.
16. Cantrell DA, Collins MKL, Crumpton MJ. Autocrine regulation of T-lymphocyte proliferation: differential induction of IL-2 and IL-2 receptor. Immunology 1988; 65: 343.
17. Kim DK, Lancki DW, Hui FH, Fitch FW. Protein kinase C dependent and independent mechanisms of cloned murine T cell proliferation. J Immunol 1989; 142: 616.
18. Isakov N, Bleakley RC, Shaw A, Altman A. The tumor promoter telocidin induces IL-2 receptor expression and IL-2 independent proliferation in human peripheral blood cells. J Immunol 1985; 135: 2343.
19. ++ dependent protein kinase. Biochem Biophys Res Commun 1986; 135: 397.
20. Davis PD, Hill CH, Keech E, et al. Potent selective inhibitors of protein kinase C. FEBS Lett 1989; 259: 61.
21. Hidaka H, Kobayashi R. Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol 1992; 32: 377.
22. Davis PD, Elliott LH, Harris W, et al. Inhibitors of protein kinase C: substituted bisindoylmaleimides with improved potency and selectivity. J Med Chem 1992; 35: 994.
23. Prince HE, John JK. Flow cytometric analysis of lymphocyte activation in the mixed lymphocyte response. Immunol Invest 1988; 17: 309.
24. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231.
25. Dumont FL, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176: 751.
26. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251.
27. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227.
28. Asaoka Y, Nakamura S, Yoshida K, Nishizuka Y. Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci 1992; 17: 414.
29. Hocevar BA, Fields AP. Selective translocation of βII protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J Biol Chem 1991; 266: 28.
30. Greif H, Ben-Chaim J, Shimon T, Bechor E, Eldar H, Livneh E. The protein kinase C related PKC-L(η) gene product is localized in the cell nucleus. Mol Cell Biol 1992; 12: 1304.
31. Hallam TJ. Functional significance of protein kinase C in human T-cell activation: a new therapeutic class? Clin Exp Rheum 1993; 11: S131.
32. Bradshaw D, Mulqueen M, Lewi E, et al. Oral anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Int J Immunopharmacol 1991; 13: 90.